Agenda Available Online

NEW YORK, NY – September 13, 2016 – The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2, 2016 at the Walter E. Washington Convention Center in Washington, DC.

Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that will impact patient care and how physicians treat heart disease. The studies selected will examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, the leading cause of death in the world. Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Sunday, October 30; Monday, October 31; Tuesday, November 1; and Wednesday, November 2. TCT press conferences will be held each morning beginning at 7:30 AM ET.

The complete agenda for TCT 2016 is now available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty. Media are invited to attend TCT. To apply for media credentials, visit: http://www.crf.org/tct/press/press-registration-form.

Sunday, October 30

Late-Breaking Trials

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery Disease

Ziad A. Ali

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients with Coronary Artery Disease

Clemens von Birgelen

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs. a Zotarolimus-Eluting Stent in a More-Comers Population of Patients with Coronary Artery Disease

David E. Kandzari

First Report Investigations

ABSORB China: Two-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Runlin Gao

ABSORB II: Three-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Patrick W. Serruys

LEADERS FREE: Two-Year Clinical and Subgroup Outcomes from a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients with Coronary Artery Disease at High Bleeding Risk

Philip M. Urban

Monday, October 31

Late-Breaking Trials

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease

Gregg W. Stone

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease

Evald H. Christiansen

First Report Investigations

REVELUTION: 9-Month Clinical, Angiographic, IVUS, and OCT Outcomes with a Polymer-Free Sirolimus-Eluting Drug-Filled Stent              

Stephen G. Worthley

FANTOM II: 6-Month and 9-Month Clinical, Angiographic and OCT Results with a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease

Alexandre Abizaid

MeRes-1: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease

Ashok Seth

FORTITUDE: 9-Month Clinical, Angiographic, and OCT Results with an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease

Antonio Colombo

FUTURE-I: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease              

Bo Xu

Tuesday, November 1

Late-Breaking Trials

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Susheel Kodali

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate Risk Patients with Severe Aortic Stenosis              

David J. Cohen

PARTNER I FIVE-YEAR ECHO: Long-Term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients with Aortic Stenosis

Pamela S. Douglas

First Report Investigations

RESPECT: Final Long-Term Outcomes From a Prospective, Randomized Trial of PFO Closure in Patients with Cryptogenic Stroke

David E. Thaler

COLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes after Stent Implantation in Patients with Coronary Artery Disease

Giora Weisz

PLATINUM DIVERSITY: Outcomes from a Large-Scale, Prospective Registry of Coronary Artery Stent Implantation in Women and Minorities

Wayne B. Batchelor

ReACT: A Prospective, Randomized Trial of Routine Angiographic Follow-up After Coronary Artery Stent Implantation

Hiroki Shiomi

Wednesday, November 2

Late-Breaking Trials       

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Sean P. Lyden

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation

Vivek Y. Reddy

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation  

David Hildick-Smith

First Report Investigations

PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients with Coronary Artery Chronic Total Occlusions

Koen Teeuwen

TOSCA-5: A Prospective, Randomized Trial Evaluating Collagenase Infusion in Patients with Coronary Artery Chronic Total Occlusions

Christopher E. Buller

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at 3 Months and Neoatherosclerosis at 18 Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Giulio Guagliumi

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis – 6-9 Month Clinical and Angiographic Follow-up Results

Fernando Alfonso

Receive updates on Twitter at http://twitter.com/TCTConference and https://twitter.com/crfheart.

Press Contacts

Irma Damhuis
Director, External Relations
Tel: 646-434-4690

Judy Romero
Program Manager, External Relations
Tel: 646-434-4608

Eucomed Guidelines go into effect
1 January 2018, update your TCTMD profile to be eligible for Grant Support to attend CRF meetings including TCT! https://www.tctmd.com/